



JCS96 USPTO

Please type a sign (+) inside this box →

(Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.)

PTO/SB/05 (11-00)

Approved for use through 10/31/2002 OMB 0651-0032

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

- Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
- Applicant claims small entity status.
See 37 CFR 1.27.
- Specification [Total Pages : 54]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement concerning Prior Art
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings *(if filed)*
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
- Drawing(s) (35 U.S.C. 113) [Total Sheets 3]
- Oath or Declaration [Total Pages 2]
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
 - i. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
- Application Data Sheet. See 37 CFR 1.76. [3 Pages]

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

 Continuation Divisional Continuation-in-Part (CIP) of prior application No: 09/265,977, filed March 11, 1999

Prior application information: Examiner: Spector, L.

Group/Art Unit: 1647

For CONTINUATION OR DIVISIONAL APPS only. The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

18. CORRESPONDENCE ADDRESS

 Customer Number or Bar Code Label 22195 or Correspondence address below

NAME			
ADDRESS			
CITY	STATE	ZIP CODE	
COUNTRY	TELEPHONE	FAX	
NAME (Print/Type)	Registration No. (Attorney/Agent) 41,119		
SIGNATURE	Date November 16, 2001		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

Attorney Docket No. PF268D1C1

First Inventor Wei et al.

Title Human Hematopoietic-Specific Protein

Express Mail Label No.

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 2023111/16/01
11/16/01

Box 82

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

Total amount of payment

\$2,084.00

Complete if Known

Application Number	Unassigned
Filing Date	Herewith
First Named Inventor	Wei et al.
Examiner Name	Unassigned
Group Art Unit	Unassigned

Attorney Docket Number

PF268D1C1

METHOD OF PAYMENT

- The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number **08-3425**

Deposit Account Name **Human Genome Sciences, Inc.**

- Charge Any Additional Fee Required
Under 37 CFR §§ 1.16 and 1.17

- Applicant claims small entity status.
See 37 CFR 1.27

Payment Enclosed:
 Check Credit Card Money Order Other

FEE CALCULATION

1-BASIC FILING FEE

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
J01	740	201	370	Utility filing fee	\$740.00
J06	330	206	165	Design filing fee	
I07	510	207	255	Plant filing fee	
J08	740	208	370	Reissuance filing fee	
J14	160	214	80	Provisional filing fee	
SUBTOTAL (1)				\$740.00	

2-EXTRA CLAIM FEES

		Extra Claims	Fee from below	Fee Paid
Total Claims	76	-20**	56	\$18.00
Independent Claims	7	-3**	4	\$84.00
Multiple Dependent				\$336.00
				\$280.00

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
108	84	209	42	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)				\$1,344.00

FEE CALCULATION (continued)

3-ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Large Entity Fee (\$)	Small Entity Fee (\$)	Fee Description
105	130	205	65	Surcharge - late filing fee or oath
127	50	227	25	Surcharge - late provisional filing fee or cover sheet
139	130	139	130	Non-English specification
147	2,520	147	2,520	For filing a request for <i>ex parte</i> reexamination requesting publication of SIR prior to Examiner action
112	920*	112	920*	Requesting publication of SIR after Examiner action
113	1,840*	113	1,840*	Extension for reply within first month
115	110	215	55	Extension for reply within second month
116	400	216	200	Extension for reply within third month
117	920	217	460	Extension for reply within fourth month
118	1,440	218	720	Extension for reply within fifth month
128	1,960	228	980	Extension for reply within sixth month
119	320	219	160	Notice of appeal
120	320	220	160	Filing a brief in support of an appeal
121	280	221	140	Request for oral hearing
138	1,510	138	1,510	Petition to institute a public use hearing
140	110	240	55	Petition to revive - unavoidable
141	1,280	241	640	Petition to revive - unintentional
142	1,280	242	640	Utility issue fee (or reissue)
143	460	243	230	Design issue fee
144	620	244	310	Plant issue fee
122	130	122	130	Petitions to the Commissioner
123	50	123	50	Processing fee under 37 CFR 1.17(q)
126	180	126	180	Submission of Information Disclosure Statement Recording each patent assignment per property (times number of properties)
581	40	581	40	Filing a submission after final rejection (37 CFR § 1.129(a)) For each additional invention to be examined (37 CFR § 1.129(b))
146	740	246	370	Request for Continued Examination (RCE) For each additional invention to be examined (37 CFR § 1.129(b))
149	740	249	370	Request for Expedited Examination of a design application
179	740	279	370	Certificate of correction
148	110	248	55	Statutory disclaimer
561	3	561	3	Printed copy of patent, regular service

Other fee (specify):

Other fee (specify):

* Reduced by Basic Filing Fee Paid

SUBTOTAL (3)

\$0.00


** or number previously paid, if greater; For Reissues, see above

Submitted By

Name (*Print/Type*) **Jonathan L. Klein**

Registration No.: **41,119**

Complete if applicable

Signature: 

Telephone: **(301) 251-6015**

Date: **November 16, 2001**

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

VIA HAND DELIVERY NOVEMBER 16, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Wei et al.

Attorney Docket No.: PF268D1C1

Application Serial No.: Unassigned

Art Unit: Unassigned

Filed: Herewith

Examiner: Unassigned

Title: Human Hematopoietic-Specific Protein


STATEMENT UNDER 37 C.F.R. § 1.821

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§1.821(f), Applicants hereby certify that the sequence listing information recorded in computer readable form and submitted herewith is identical to the written (on paper) Sequence Listing submitted herewith.

Respectfully submitted,


Jonathan L. Klein
Attorney for Applicants

Reg. No. 41,119

Dated: November 16, 2001

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 251-6015

JLK/CCB/ba

FINGERPRINT 236438660